New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

  • Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00733-19. doi: 10.1128/AAC.00733-19.
Amit Kaushik  1 ,  Nicole C Ammerman  1 ,  Nicole M Parrish  2 ,  Eric L Nuermberger  3
Affiliations
  • 1. Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • 2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • 3. Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA [email protected].
PMID: 31209013 DOI: 10.1128/AAC.00733-19
Abstract

The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the in vitro activity of β-lactam Antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of Other β-lactams, similar to prior results with avibactam and relebactam.

Keywords
Mycobacterium abscessus; cefepime; diazabicyclooctane; drug susceptibility assay; meropenem; nacubactam; zidebactam; β-lactamase inhibitors; β-lactams.
Products